Marco Armenante

Marco Armenante is a Senior Scientist in Engineering at Merck, specializing in Chemical Commercialization Technology since June 2016, where notable contributions include leading the development of a novel enzymatic reaction for Islatravir and managing over 10 production batches for various intermediates. Previous roles in Merck involved driving research for synthetic processes and scaling API production. Prior academic experience includes graduate research at the University of Delaware focused on thermochemistry and modeling, and various teaching roles at Rutgers University. Education includes a Master of Science in Chemical Engineering from the University of Delaware, a Bachelor of Science in Chemical Engineering from Rutgers University, and ongoing studies for a Master of Science in Computer Science at the Georgia Institute of Technology.